The new Single programming document sets out the EMCDDA’s activities for the period 2021–2023, marking the start of a new five-year roadmap under Strategy 2025. At the heart of the agency’s work in 2021 will be the development of a new business model, which places customers and digital transformation at its core. The main activities include the further development of information collection and analysis methods, cooperation with the EMCDDA's networks at the EU and international level, collaboration within the Instrument for Pre-accession Assistance (IPA 7) and EU4Monitoring Drugs (EU4MD) projects, and a bilateral project with Georgia (EMCDDA4GE). Among the main outputs for 2021 are the European Drug Report, a new Responses guide and an Insights publication on prison and drugs in Europe.